CN106404636A - Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof - Google Patents
Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof Download PDFInfo
- Publication number
- CN106404636A CN106404636A CN201610783598.5A CN201610783598A CN106404636A CN 106404636 A CN106404636 A CN 106404636A CN 201610783598 A CN201610783598 A CN 201610783598A CN 106404636 A CN106404636 A CN 106404636A
- Authority
- CN
- China
- Prior art keywords
- edta
- false
- thrombocytopenia
- dependency
- anticoagulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 210000004369 blood Anatomy 0.000 title claims abstract description 57
- 239000008280 blood Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000001419 dependent effect Effects 0.000 title abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 80
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 74
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims abstract description 68
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 62
- 239000011775 sodium fluoride Substances 0.000 claims abstract description 34
- 235000013024 sodium fluoride Nutrition 0.000 claims abstract description 34
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 31
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 31
- 239000011718 vitamin C Substances 0.000 claims abstract description 31
- 238000007789 sealing Methods 0.000 claims abstract description 18
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims abstract description 17
- 229960004821 amikacin Drugs 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 63
- 206010043554 thrombocytopenia Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 239000000306 component Substances 0.000 claims description 14
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims description 10
- 229960001656 amikacin sulfate Drugs 0.000 claims description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- 238000001514 detection method Methods 0.000 abstract description 9
- 239000002131 composite material Substances 0.000 abstract 3
- 230000000694 effects Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 7
- 229940127090 anticoagulant agent Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- RKQKLZMMOQWTGB-HYBUGGRVSA-N diphenyl-[(1R,2S)-2-(phenylsulfanylmethyl)cyclopentyl]phosphane Chemical compound C([C@@H]1[C@@H](CCC1)P(C=1C=CC=CC=1)C=1C=CC=CC=1)SC1=CC=CC=C1 RKQKLZMMOQWTGB-HYBUGGRVSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
The invention provides a tube and a blood collection tube capable of avoiding the appearance of EDTA dependent pseudothrombocytopenia (PTCP), and a preparation method thereof. The blood collection tube comprises a tube body and a sealing member that cooperate with each other. A composite anticoagulant is formed on the internal wall of the tube body and comprises EDTA salts, sodium fluoride, vitamin C, and a component A, which is amikacin or pharmaceutically acceptable salts of amikacin. The preparation method comprises the following steps: mixing EDTA salts, sodium fluoride, vitamin C, and the component A to prepare a composite anticoagulant; then adding the composite anticoagulant into a tube body, drying the tube body at a temperature of 50 to 60 DEG C, assembling a sealing member onto the tube body, and maintaining a negative pressure in the tube body. The provided blood collection tube can prevent EDTA-PTCP, and thus effectively avoids the appearance of EDTA-PTCP; the detection results are real and reliable, and the misdiagnosis and mistreatment are reduced.
Description
Technical field
The present invention relates to field of medical examination, avoid the false thrombocytopenia of EDTA dependency in particular to one kind
Body and blood taking tube and preparation method that disease occurs.
Background technology
Ethylenediaminetetraacetic acid (EDTA) Shi Yibei world hematology standard committee (ICSH) assert complete as Clinical Laboratory
The general anticoagulant of blood cell analysis, is usually used in clinical treatment blood routine item detection, including platelet count.Facing
Bed is extensively applied.In recent years constantly it has been reported that, the patient of 0.09%-0.21%, in blood routine examination, blood preparation is taken out
After entering potassium salt containing EDTA or the vacuum test tube of sodium salt, there is platelet aggregation in very short time.When these specimen are carried out
During analysis detection, the platelet sticking gathering is not regarded as platelet, causes the false reduction of platelet count result.Clinically
The platelet that the non-body disturbances of blood coagulation of this EDTA anticoagulant effect leads to measures and reduces phenomenon referred to as EDTA dependency
False thrombocytopenia (EDTA-dependent pseudothrombodytopenia, EDTA-PTCP).
EDTA-PTCP is a kind of external phenomenon, and non-diseases, does not have any clinical meaning, this phenomenon i.e. it may happen that
In healthy population it is also possible to betide the patient with various diseases, and the generation with disease is not directly dependent upon with improvement, very
To unsoundness people for a long time with this phenomenon.Although the no special pathology sense of EDTA-PTCP, it usually gives clinical position
Person brings a lot of puzzlements, both may cause mistaken diagnosis, the wrong treatment of disease, and for no reason increase financial burden and the mental burden of patient.
Content of the invention
The first object of the present invention is to provide a kind of body avoiding the false thrombocytopenia of EDTA dependency to occur,
Compound anticoagulant is attached with the inwall of this body, the appearance of EDTA-PTCP can be prevented effectively from, be i.e. either normal person
Or EDTA-PTCP patient, can carry out anticoagulant using this body.
The second object of the present invention is to provide a kind of blood sampling avoiding the false thrombocytopenia of EDTA dependency to occur
Pipe, using this blood taking tube, can resist EDTA-PTCP, so that testing result is genuine and believable, and be avoided that the later stage multiple
Look into the loaded down with trivial details process such as rectification.
The third object of the present invention is to provide a kind of described false thrombocytopenia of EDTA dependency that avoids to occur
Body preparation method.In the body that this method is obtained, compound anticoagulant attachment is uniform, and process is simple, suitable industrialization
Produce.
The fourth object of the present invention is to provide a kind of described false thrombocytopenia of EDTA dependency that avoids to occur
Blood taking tube preparation method.This method preparation process is simple, simple to operate when being taken a blood sample using this blood taking tube, easily
Realize.
In order to realize the above-mentioned purpose of the present invention, spy employs the following technical solutions：
A kind of body avoiding the false thrombocytopenia of EDTA dependency to occur, the inwall of body is formed with compound anticoagulant
Agent, compound anticoagulant includes edta salt, sodium fluoride, vitamin C and component A, and component A is amikacin or medicine is acceptable
The salt of amikacin.
A kind of avoid the false thrombocytopenia of EDTA dependency occur blood taking tube, including above-mentioned tubular body, and with upper
State the sealing member that body cooperates.
A kind of preparation method of the body avoiding the false thrombocytopenia of EDTA dependency to occur, comprises the following steps：
Edta salt, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again compound anticoagulant is made an addition to pipe
In vivo, and in 50-60 DEG C of drying.
A kind of preparation method of the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, according to the method described above
Prepare body, subsequently assemble sealing member, and make to keep negative pressure in body.
In order to avoid the error result that EDTA-PTCP causes occurs, at present clinically using check blood sampling, and carry out handss
Work smear platelet count, or to be taken a blood sample again reinspection using sodium citrate anticoagulant tube, sodium fluoride anticoagulant tube, or adopting
Combine in and in the blood sample of EDTA anticoagulant tube, add amikacin to carry out remedial measure.The method that these checks are corrected is all a kind of
Afterwards make up method, if sufficiently EDTA-PTCP can not be identified early, easily cause mistaken diagnosis and increase some not
Other auxiliary examinations necessary；And identification needs, through patient is reviewed, checks etc. with loaded down with trivial details process, to increase patient's pain afterwards
Bitter thereby increases and it is possible to delay treatment.
Compared with prior art, beneficial effects of the present invention are：
Compound anticoagulant is attached with the inwall of this body, this compound anticoagulant can resist EDTA-PTCP, from
And being prevented effectively from the appearance of EDTA-PTCP, i.e. either normal person or EDTA-PTCP patient, using with this body
Blood taking tube or other container all without the phenomenon that the false minimizing of platelet occurs so that testing result is genuine and believable,
Reduce mistaken diagnosis, the situation of wrong treatment occurs.
This body from the beginning it is avoided that EDTA-PTCP occurs, rather than can identify as prior art afterwards
After going out EDTA-PTCP, then patient carried out review, check etc. with loaded down with trivial details process.Therefore, using this with compound anticoagulant
Body, conveniently, safely, fast, and being avoided that the consumption of human and material resources, shortening Diagnostic Time, thus ensureing the life of patient
Safety.
Additionally, compound anticoagulant attachment uniformly, resists EDTA- in the body being obtained by the preparation method of this body
The effect is significant of PTCP, and the process is simple of this method, suitable industrialized production.Meanwhile, using with this body
The same with the operation using general blood collection tube when blood taking tube is taken a blood sample, simple, easily realize.
Specific embodiment
Below in conjunction with embodiment, embodiment of the present invention is described in detail, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and be not construed as limiting the scope of the present invention.Unreceipted concrete in embodiment
Condition person, the condition according to normal condition or manufacturer's suggestion is carried out.Agents useful for same or the unreceipted production firm person of instrument, are
Can be by the commercially available conventional products bought and obtain.
Present embodiment provides a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, including mutually
The body of cooperation and sealing member, the inwall of body is formed with compound anticoagulant, and compound anticoagulant includes edta salt, sodium fluoride, dimension
Raw element C and component A, component A is the salt of amikacin or medical acceptable amikacin.
Compound anticoagulant is attached with the inwall of this body, this compound anticoagulant can resist EDTA-PTCP, from
And being prevented effectively from the appearance of EDTA-PTCP, i.e. either normal person or EDTA-PTCP patient, using with this body
Blood taking tube or other container all without the phenomenon that the false minimizing of platelet occurs so that testing result is genuine and believable,
Reduce mistaken diagnosis, the situation of wrong treatment occurs.
This body from the beginning it is avoided that EDTA-PTCP occurs, rather than can identify as prior art afterwards
After going out EDTA-PTCP, then patient carried out review, check etc. with loaded down with trivial details process.Therefore, using this with compound anticoagulant
Body, conveniently, safely, fast, and being avoided that the consumption of human and material resources, shortening Diagnostic Time, thus ensureing the life of patient
Safety.
The appearance of EDTA-PTCP, the effect because of EDTA makes the antigen on platelet membrane surface change or hidden
Antigen-exposed, thus causing antigen antibody reaction, therefore in EDTA-PTCP, EDTA effect is cut in, thus leading to blood little
Plate is assembled.Amikacin in the compound anticoagulant that the present invention provides and vitamin C belong to aminoglycosides antibiotics, Neng Goulian
Close the activation of suppression platelet membrane surface fibrillar proteins original receptor, thus stoping Fibrinogen from being attached to the receptor of platelet membrane
On, directly block the platelet aggregation that antigen antibody reaction occurs.And sodium fluoride is inhibitor of phospholipase enzymes, and promote platelet born of the same parents
Interior flow of calcium ions, improves cAMP level, thus suppressing platelet aggregation and release so that this compound anticoagulant resists EDTA-
The effect of PTCP strengthens.
In preferred embodiments of the present invention, above-mentioned compound anticoagulant count by weight including：Edta salt is 14-22
Part, sodium fluoride is 5-8 part, and vitamin C is 5-8 part, and component A is 20-50 part.Four kinds of compositions in compound anticoagulant press this
When the ratio of kind carries out proportioning, the effect of antagonism EDTA-PTCP is strong, effect is significant.
It is further preferred that above-mentioned edta salt is 15-20 part, sodium fluoride is 6-7 part, and vitamin C is 6-7 part, component
A is 30-50 part.Highly preferred, above-mentioned edta salt is 18.5 parts, and sodium fluoride is 6 parts, and vitamin C is 6 parts, and component A is 45
Part.In this ratio range, the effect of compound anticoagulant EDTA-PTCP further enhances.
In preferred embodiments of the present invention, above-mentioned edta salt is selected from EDTA-K2, EDTA-K3 and EDTA-Na2
Any one.EDTA-K2 and EDTA-K3 is the potassium salt of EDTA, and EDTA-Na2 is the disodium salt of EDTA.These three salt are all
It is usually used in the general anticoagulant of Clinical Laboratory whole blood cell analysis, safely and effectively.
In preferred embodiments of the present invention, the salt of above-mentioned medical acceptable amikacin is amikacin sulfate.Ah
Meter Ka Xing, is commonly called as amikacin, is the antibiotic clinically commonly used.And amikacin sulfate is the sulphuric acid of amikacin
Salt, it is possible to increase the stability of amikacin and permeability, and then extend the effect duration of this blood taking tube.
In preferred embodiments of the present invention, the material of above-mentioned tubular body is glass or plastics.Glass and plastics often by with
To make blood taking tube, in this programme, glass is use for laboratory neutral density glass；Plastics are PET, the vacuum of both materials
Keep and the stable effect of moisture content is good.
Present embodiment also provides a kind of preparation side of the body avoiding the false thrombocytopenia of EDTA dependency to occur
Method, comprises the following steps：Edta salt, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；To answer again
Close anticoagulant to make an addition in body, and in 50-60 DEG C of drying.
Present embodiment also provides a kind of preparation of the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur
Method, prepares body according to the method described above, subsequently assembles sealing member, and makes to keep negative pressure in body.
In the body being obtained by the preparation method of this body, compound anticoagulant attachment uniformly, resists EDTA-PTCP's
Effect is significant, and the process is simple of this method, suitable industrialized production.Meanwhile, using the blood taking tube with this body
The same with the operation using general blood collection tube when being taken a blood sample, simple, easily realize.
50-60 DEG C of drying of selection, preferably 55 DEG C, it can be avoided that the component in compound anticoagulant is tied in hot environment
Structure is destroyed.After the drying, also need through steps such as conventional sterilizings.Keep negative pressure in body, be conducive to that takes a blood sample smoothly to enter
OK.
In preferred embodiments of the present invention, above-mentioned compound anticoagulant is by way of metered dose or quantitative Deca
Mode makes an addition in body.By the way of metered dose, controllability is strong, and spray effect is good, enables to compound anticoagulant
Uniformly it is attached to the inwall of body, so that the effect of anti-EDTA-PTCP is good.By the way of quantitative Deca, affected letter
Just, the requirement to required instrument and equipment is low.
In preferred embodiments of the present invention, above-mentioned sealing member is rubber stopper, adopts aspirator after assembling sealing member
Make to keep negative pressure in body.The good sealing effect of rubber stopper, is suctioned out the air in body so that in body using aspirator
Keep negative pressure, operation is simple.
In preferred embodiments of the present invention, the ratio between the quality of the volume of above-mentioned tubular body and compound anticoagulant is：
The compound anticoagulant adding in the body of every 1mL volume includes：Edta salt is 1.4-2.2mg, and sodium fluoride is 0.5-0.8mg,
Vitamin C is 0.5-0.8mg, and component A is 2.0-5.0mg.
Anticoagulant 1mL blood, the amount of the compound anticoagulant of needs is：Edta salt is 1.4-2.2mg, and sodium fluoride is 0.5-
0.8mg, vitamin C is 0.5-0.8mg, and component A is 2.0-5.0mg.According to this proportioning, can foundation when preparing blood taking tube
The volume of body, the amount of every kind of component in compound anticoagulant needed for calculating, so that the blood taking tube of plurality of specifications is respectively provided with very well
Anticoagulant effect.
Embodiment 1
The present embodiment provide a kind of avoid the false thrombocytopenia of EDTA dependency occur body, this body interior
Wall is formed with compound anticoagulant, and compound anticoagulant includes EDTA-K2, sodium fluoride, vitamin C and component A, and component A is Ah rice
Card star.
These four components of compound anticoagulant are counted by weight, and EDTA-K2 is 22 parts, and sodium fluoride is 8 parts, vitamin C
For 8 parts, amikacin is 20 parts.
The preparation method of this body is：
EDTA-K2, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again by compound anticoagulant
Agent is made an addition in body by way of metered dose, and in 50 DEG C of dryings, obtains final product.
Embodiment 2
The present embodiment provide a kind of avoid the false thrombocytopenia of EDTA dependency occur body, this body interior
Wall is formed with compound anticoagulant, and compound anticoagulant includes EDTA-K3, sodium fluoride, vitamin C and component A, and component A is Ah rice
Card star.
These four components of compound anticoagulant are counted by weight, and EDTA-K3 is 15 parts, and sodium fluoride is 7 parts, vitamin C
For 7 parts, amikacin is 30 parts.
The preparation method of this body is：
EDTA-K3, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again by compound anticoagulant
Agent is made an addition in body by way of quantitative Deca, and in 60 DEG C of dryings, obtains final product.
Embodiment 3
The present embodiment provides a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, this blood taking tube
Including the body cooperating and sealing member, the inwall of body is formed with compound anticoagulant, and compound anticoagulant includes EDTA-
Na2, sodium fluoride, vitamin C and component A, component A is amikacin sulfate.
These four components of compound anticoagulant are counted by weight, and EDTA-Na2 is 18.5 parts, and sodium fluoride is 6 parts, dimension life
Plain C is 6 parts, and amikacin sulfate is 45 parts.
The preparation method of this blood taking tube is：
EDTA-Na2, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again by compound anticoagulant
Agent is made an addition in body by way of metered dose, and in 55 DEG C of dryings, subsequently assembles sealing member, and makes to keep negative in body
Pressure.
Embodiment 4
The present embodiment provides a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, this blood taking tube
Including the body cooperating and sealing member, the inwall of body is formed with compound anticoagulant, compound anticoagulant include EDTA-K2,
Sodium fluoride, vitamin C and component A, component A is amikacin sulfate.
These four components of compound anticoagulant are counted by weight, and EDTA-K2 is 20 parts, and sodium fluoride is 6 parts, vitamin C
For 6 parts, amikacin sulfate is 50 parts.
The preparation method of this blood taking tube is：
EDTA-K2, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again by compound anticoagulant
Agent makes an addition in body by way of quantitative Deca, and body is glass material, and in 60 DEG C of dryings, subsequently assembles sealing member,
Sealing member is rubber stopper, subsequently makes to keep negative pressure in body using aspirator.
Embodiment 5
The present embodiment provides a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, this blood taking tube
Including the body cooperating and sealing member, the inwall of body is formed with compound anticoagulant, and compound anticoagulant includes EDTA-
Na2, sodium fluoride, vitamin C and component A, component A is amikacin sulfate.
These four components of compound anticoagulant are counted by weight, and EDTA-Na2 is 14 parts, and sodium fluoride is 5 parts, vitamin
C is 5 parts, and amikacin sulfate is 50 parts.
The preparation method of this blood taking tube is：
EDTA-Na2, sodium fluoride, vitamin C and component A are mixed, is configured to compound anticoagulant；Again by compound anticoagulant
Agent is made an addition in body by way of metered dose, and body is plastic material, and in 55 DEG C of dryings, subsequently assembles sealing member,
And make to keep negative pressure in body.
Embodiment 6
The present embodiment provides a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur, with embodiment 3
Similar, difference is, the body volume of this blood taking tube is 1mL, the quality of four components in required compound anticoagulant
It is respectively：EDTA-Na2 is 1.85mg, and sodium fluoride is 0.6mg, and vitamin C is 0.6mg, and amikacin sulfate is 4.5mg.
Experimental example
With reference to clinical trial to employing pipe provided in an embodiment of the present invention antagonism EDTA-PTCP in terms of effect
Evaluated.
This blood taking tube being provided using the embodiment of the present invention 6, routinely blood-sampling method, EDTA- is confirmed as in collection 6
The blood sample of PTCP patient, the same period adopts platelets by manual collection counting method (criterion keying method), sodium citrate anticoagulant tube detection method
Compare with common EDTA-K2 anticoagulant tube detection method.
Platelet is measured after blood sampling respectively, its platelet measured value record is in table 1 when 10min, 2h and 4h.Other are implemented
The result of the test of example is consistent with embodiment 6, therefore does not list one by one.
The table 1.EDTA-PTCP blood samples of patients specimen platelet measured value (× 10 of different detection methods9/L)
As shown in Table 1, with platelets by manual collection counting method (criterion keying method), sodium citrate anticoagulant tube detection method, common
The result of EDTA-K2 anticoagulant tube detection method is compared, the blood taking tube being provided using the present invention, the platelet of detection in 10 minutes
Count no significant difference (ρ ＞ 0.05).Surveyed using the blood taking tube and manual method (criterion keying method) of the present invention after 2-4 hrs
Determine result no significant difference (ρ ＞ 0.05), and other methods of inspection (sodium citrate anticoagulant tube and common EDTA anticoagulant tube) and handss
There were significant differences for engineering method (criterion keying method) measurement result (ρ ＜ 0.01).The blood taking tube that thus the explanation present invention provides, can be right
Anti- EDTA-PTCP, thus being prevented effectively from the appearance of EDTA-PTCP, so that testing result is genuine and believable, minimizing mistaken diagnosis,
The situation of wrong treatment occurs.
Although illustrate and describing the present invention with specific embodiment, but it will be appreciated that without departing substantially from the present invention's
Many other changes can be made in the case of spirit and scope and change.It is, therefore, intended that in the following claims
Including all such changes and modifications belonging in the scope of the invention.
Claims (10)
1. a kind of body avoiding the false thrombocytopenia of EDTA dependency to occur is it is characterised in that the inwall of described body
It is formed with compound anticoagulant, described compound anticoagulant includes edta salt, sodium fluoride, vitamin C and component A, and described component A is
Amikacin or the salt of medical acceptable amikacin.
2. a kind of blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur is wanted it is characterised in that including right such as
Ask the body described in 1, and the sealing member cooperating with described body.
3. the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 2, its feature exists
In, described compound anticoagulant count by weight including：
Described edta salt is 14-22 part, and described sodium fluoride is 5-8 part, and described vitamin C is 5-8 part, and described component A is
20-50 part.
4. the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 3, its feature exists
In described edta salt is 15-20 part, and described sodium fluoride is 6-7 part, and described vitamin C is 6-7 part, and described component A is
30-50 part.
5. the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 2, its feature exists
In described edta salt is selected from any one in EDTA-K2, EDTA-K3 and EDTA-Na2.
6. the blood taking tube avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 2, its feature exists
In the salt of described medical acceptable amikacin is amikacin sulfate.
7. a kind of preparation side of the body avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 1
Method is it is characterised in that comprise the following steps：
Described edta salt, described sodium fluoride, described vitamin C and component A are mixed, is configured to compound anticoagulant；Again by institute
State compound anticoagulant to make an addition in described body, and in 50-60 DEG C of drying.
8. a kind of false thrombocytopenia of EDTA dependency that avoids according to any one of claim 2-6 occurs
The preparation method of blood taking tube, it is characterised in that preparing described body in accordance with the method for claim 7, is subsequently assembled described
Sealing member, and make to keep negative pressure in described body.
9. the preparation method of the body avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 7,
It is characterized in that, by way of metered dose or the mode of quantitative Deca makes an addition to described body to described compound anticoagulant
Interior.
10. the preparation method of the body avoiding the false thrombocytopenia of EDTA dependency to occur according to claim 7,
It is characterized in that, the ratio between the quality of the volume of described body and described compound anticoagulant is：The described pipe of every 1mL volume
The internal described compound anticoagulant adding includes：Described edta salt is 1.4-2.2mg, and described sodium fluoride is 0.5-0.8mg, institute
Stating vitamin C is 0.5-0.8mg, and described component A is 2.0-5.0mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610783598.5A CN106404636A (en) | 2016-08-31 | 2016-08-31 | Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610783598.5A CN106404636A (en) | 2016-08-31 | 2016-08-31 | Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106404636A true CN106404636A (en) | 2017-02-15 |
Family
ID=58001433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610783598.5A Pending CN106404636A (en) | 2016-08-31 | 2016-08-31 | Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106404636A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913348A (en) * | 2017-03-31 | 2017-07-04 | 汪学耀 | A kind of pre-dilution vacuum test tube and measurement platelet count purpose method |
| CN107271348A (en) * | 2017-07-06 | 2017-10-20 | 苏州大学 | A kind of medical artificial pipeline permeance property test system and its application method |
| CN109998561A (en) * | 2019-05-15 | 2019-07-12 | 广西中医药大学附属瑞康医院 | Disposable blood coagulation vacuum blood collection tube |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056893B2 (en) * | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| CN102466730A (en) * | 2010-11-19 | 2012-05-23 | 南京神州英诺华医疗科技有限公司 | Novel method for matching blood reverse typing reagent |
| CN102620950A (en) * | 2012-03-21 | 2012-08-01 | 安徽信灵检验医学科技有限公司 | Platelet preserving agent |
| CN202458389U (en) * | 2012-02-07 | 2012-10-03 | 山东侨牌集团有限公司 | Disposable vacuum blood collecting tube |
| CN102973943A (en) * | 2012-12-17 | 2013-03-20 | 李大鹏 | Novel blood storage anticoagulant and preparation method thereof |
| CN103323296A (en) * | 2012-03-23 | 2013-09-25 | 南京柯伦迪检测技术有限公司 | Anticoagulant agent match use method for blood platelet function detection |
-
2016
- 2016-08-31 CN CN201610783598.5A patent/CN106404636A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056893B2 (en) * | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| CN102466730A (en) * | 2010-11-19 | 2012-05-23 | 南京神州英诺华医疗科技有限公司 | Novel method for matching blood reverse typing reagent |
| CN202458389U (en) * | 2012-02-07 | 2012-10-03 | 山东侨牌集团有限公司 | Disposable vacuum blood collecting tube |
| CN102620950A (en) * | 2012-03-21 | 2012-08-01 | 安徽信灵检验医学科技有限公司 | Platelet preserving agent |
| CN103323296A (en) * | 2012-03-23 | 2013-09-25 | 南京柯伦迪检测技术有限公司 | Anticoagulant agent match use method for blood platelet function detection |
| CN102973943A (en) * | 2012-12-17 | 2013-03-20 | 李大鹏 | Novel blood storage anticoagulant and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周小棉 等: "丁胺卡那霉素抑制和解离抗凝剂依赖的假性血小板聚集作用研究", 《中华检验医学杂志》 * |
| 巫小莉 等: "EDTA-丁胺卡那抗凝管稳定期的研究", 《实验与检验医学》 * |
| 鲁家才 等: "两种药物对EDTA 依赖性血小板聚集的抑制作用", 《临床检验杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913348A (en) * | 2017-03-31 | 2017-07-04 | 汪学耀 | A kind of pre-dilution vacuum test tube and measurement platelet count purpose method |
| CN106913348B (en) * | 2017-03-31 | 2023-06-23 | 汪学耀 | Pre-diluted vacuum blood collection tube and method for measuring platelet number |
| CN107271348A (en) * | 2017-07-06 | 2017-10-20 | 苏州大学 | A kind of medical artificial pipeline permeance property test system and its application method |
| CN109998561A (en) * | 2019-05-15 | 2019-07-12 | 广西中医药大学附属瑞康医院 | Disposable blood coagulation vacuum blood collection tube |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grubb et al. | First certified reference material for cystatin C in human serum ERM-DA471/IFCC | |
| Loh et al. | Trends and physiology of common serum biochemistries in children aged 0–18 years | |
| Robinson et al. | Erythrocytes: a new cell type for the evaluation of insulin receptor defects in diabetic humans | |
| CN102621332B (en) | Retinol binding protein assay kit based on latex particle coating | |
| CN101221189B (en) | External diagnostic reagent kit used for measuring activated partial thromboplastin time | |
| CN106198961A (en) | The latex of a kind of detection by quantitative serum amyloid A protein strengthens Immunoturbidimetric kit and preparation method thereof | |
| KR101822368B1 (en) | Lyophilised Dabigatran | |
| CN106404636A (en) | Tube and blood collection tube capable of avoiding appearance of EDTA dependent pseudothrombocytopenia (PTCP), and preparation method thereof | |
| CN106872718A (en) | A kind of microdose urine protein detection kit and preparation method thereof | |
| CN103076455A (en) | Kit for quickly and quantificationally detecting serum amyloid A, and preparation and application thereof | |
| CN102012433A (en) | Avian influenza virus H9 subtype positive blood serum and negative blood serum standard substances and preparation methods thereof | |
| CN106290907A (en) | Serum amyloid A protein quantitative detecting reagent and detection method in whole blood | |
| CN103389383A (en) | Detection kit for measuring content of myohemoglobin in serum | |
| CN105368915B (en) | Prothrombin time determination reagent box and preparation method thereof | |
| CN107271234A (en) | Urinary formed element analyzer Quality Control thing/control material and preparation method thereof | |
| Degen et al. | Predictive performance of different kidney function estimation equations in lung transplant patients | |
| Greenway et al. | Point-of-care monitoring of oral anticoagulation therapy in children | |
| CN106645665A (en) | Thrombin time detection reagent | |
| US20060194191A1 (en) | Processing method for the long-term stabilization of biological red blood cell volume | |
| CN105368916B (en) | A kind of prothrombin time determination reagent box and preparation method thereof | |
| CN106932350A (en) | Blood cell analysis hemolytic agent | |
| US6146901A (en) | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition | |
| US10724953B2 (en) | Method for evaluating phagocytic capacity and fluorescence measurement method | |
| RU2463610C1 (en) | METHOD FOR MAKING PANEL OF HBsAg SUBTYPES AD AND AY SERUMS FOR QUALITY CONTROL OF DIAGNOSING HEPATITIS B | |
| CN105137095B (en) | The immunoassay kits of free thyroxine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |